Background-Substantial evidence-practice gaps exist in the management of acute coronary syndromes (ACS) in China.
T he burden of chronic, noncommunicable disease, including cardiovascular disease, has increased rapidly and substantially in China in recent years. 1 During coming decades, this country is predicted to experience a 69% increase in acute coronary disease (≈8 million additional events) compared with the decade 2000 to 2009. 2 More than two thirds of the burden of death and disability from acute coronary syndromes (ACS) will occur in adults aged <65 years. 2 The ability of the Chinese healthcare system to respond to this problem is critical, but there is growing public concern about access, cost, and quality of health care. 3 Recent studies have highlighted important gaps between best evidence and practice in the hospital management of ACS in China, 4, 5 many of which have also been reported in other countries. [6] [7] [8] Clinical pathways are management plans that provide the sequence and timing of actions necessary to achieve patient goals with optimal efficiency and are commonly used for conditions of high volume and cost such as ACS. 9 Justification for their extensive use in the management of ACS, especially in high-income settings, is largely based on evidence from observational studies 10, 11 rather than randomized trials. As part of recent health reforms, 12 the Chinese Ministry of Health has endorsed clinical pathway use for >300 different conditions, including ACS. 13 The Clinical Pathways for Acute Coronary Syndromes-Phase 2 (CPACS-2) Study was a large cluster randomized trial that sought to provide rigorous evidence to inform the routine use of clinical pathways in the management of ACS in China.
Methods
A cluster randomized trial with mixed methods evaluation was conducted. The study protocol has been published. 14 This trial was registered with the Australian and New Zealand Clinical Trials Register.
Participating Hospitals
Urban hospitals throughout China routinely admitting ≥100 patients annually with suspected ACS were eligible. The study sought to include both level 2 (broadly defined as regional hospitals providing medical services to several communities) and level 3 (broadly defined as hospitals providing high level specialist medical services to several geographic regions) centers.
Hospital Randomization
Using a central computer-based system, 70 participating hospitals were randomly allocated, stratified by hospital level, to 1 of 2 groups: group A in which hospitals implemented the pathway early (the intervention group), and group B (the control group) in which hospitals implemented the pathway late (12 months after group A).
Patient Population and Recruitment
Data from adult patients (aged ≥18 years) with a final diagnosis of ACS identified at the time of death or discharge were included. Patients were assigned a clinical diagnosis of ACS according to the treating physician. Each hospital was required to collect data from 50 consecutive patients at baseline and at 6-month intervals thereafter. An admission record provided evidence of the consecutive inclusion. Deidentified data were entered into a web-based case report form (primary patient questionnaire, follow-up questionnaire, and manual of operation are provided in Data Supplement materials). These included patient demographic characteristics, initial assessment and diagnosis, investigations, use of reperfusion therapy (thrombolysis or primary percutaneous coronary intervention [PCI]) or revascularization (PCI or coronary artery bypass grafting), medications, final diagnosis (ST-segment-elevation myocardial infarction [STEMI], non-ST-segment-elevation myocardial infarction, or unstable angina pectoris), in-hospital events, and costs of hospitalization. Data were collected and entered by trained personnel not involved in the clinical care of the patients.
Clinical Pathway Intervention
The intervention was the implementation of clinical care pathways. Three major generic clinical pathways (risk stratification, management of STEMI, and management of non-ST-segment-elevation myocardial infarction/unstable angina pectoris) were developed in conjunction with the Chinese Society of Cardiology based on the relevant American Heart Association and American College of Cardiology guidelines (provided in Data Supplement materials). 15, 16 The pathways were modified for the Chinese context on the basis of expert advice from a working group comprising 22 cardiologists representing both level 2 and level 3 hospitals. This working group also recommended changes to generic pathways based on the feasibility, relevance, and applicability of the pathways to each level of hospital, including availability of resources. Therefore, the study did not attempt to ensure strict standardization of the intervention but rather adopt an approach consistent with complex intervention guidelines that support tailoring interventions to local circumstances. 17 A team comprising clinical representatives from each department with responsibilities relevant to the management of patients with ACS and led by a senior hospital cardiologist undertook responsibility for pathway implementation. To avoid contamination, pathway training was provided at 2 separate investigator meetings held immediately before each group commencing the study (ie, 12 months apart). At baseline and every 6 months subsequently, data from 50 consecutive patients with a diagnosis of ACS were collected at each hospital, and a report on each hospital's performance (based on prespecified key performance indicators [KPIs]) was provided in real-time to clinicians via a web-based system. These reports allowed hospitals to measure their own performance against a standard benchmark. 18 In the event of any suboptimal results, hospitals were encouraged to modify relevant aspects of the pathway in an effort to improve performance.
Outcome Measures
The primary outcomes were KPIs as follows; (1) proportion of patients with final diagnosis consistent with biomarker findings, (2) proportion of patients with STEMI receiving thrombolysis or primary PCI among those arriving within 12 hours of symptom onset, (3) door-to-needle time for patients with STEMI undergoing thrombolysis, (4) door-to-balloon time for patients with STEMI undergoing primary PCI, (5) proportion of high-risk patients undergoing coronary angiography, (6) proportion of low-risk patients (no ongoing symptoms, persistently normal ECG, and persistently normal biomarkers) undergoing functional testing, (7) proportion of patients discharged on combination medical therapy (including any antiplatelet therapy, β-blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and statin), and (8) hospital length of stay. These key performance variables were selected because of evidence from previous studies, 4,5 unexplained variation from guideline recommendations, and documented association with clinical outcomes and cost-effective care. Secondary outcomes were in-hospital clinical events: (1) death (2) cardiac death (3) major adverse cardiovascular events comprising all-cause mortality, myocardial infarction, and stroke, and (4) major bleeding episodes.
WHAT IS KNOWN
• The burden of coronary heart disease is rapidly rising in China and is associated with a large increase of patients presenting with acute coronary syndromes. • Clinical pathways for improving the use of evidence-based treatment for acute coronary syndromes are commonly used in Western countries, but their effectiveness in hospitals in China has not been examined previously.
WHAT THE STUDY ADDS
• Clinical pathways had a limited effect on improving guideline-recommended processes of care for acute coronary syndromes, although this study had insufficient power to make definitive conclusions. • System-level barriers to successful implementation of the clinical pathways were identified and are outlined in an accompanying article. 20
Sample Size Calculations and Statistical Analysis
An earlier study 4 of ACS management in China (CPACS-1) informed sample size estimations. We did not specify a single primary outcome on which to power the study or to declare the intervention effective or ineffective because there was no clear scientific rationale for preferentially selecting 1 outcome, or subgroup of outcomes, over another, particularly given that not all KPIs were relevant to all clinical ACS syndromes considered. Initial power calculations used outcomes measured in the entire population of patients, assuming 70 hospitals (35 per group) and an average of 50 patients per hospital. Based on these calculations, the study had 90% power to detect an increase in the proportion of patients discharged on combination secondary prevention therapies (aspirin, statin, ACE-inhibitor, and β-blocker) from 50% to 60% or greater, assuming an intraclass correlation coefficient of 0.05 and an average cluster size of 50. This sample size also provided ≥80% power to detect an increase in provision of reperfusion therapy to patients with STEMI arriving at hospital within 12 hours of symptom onset from 35% to 45% or greater; a reduction in diagnoses inconsistent with biomarker findings from 20% to 13% or lower; an increase in functional testing among low-risk patients from 2% to 6% or greater; an increase in coronary angiography among high-risk patients from 40% to 50% or greater; a reduction from 14 to 5 days for length of hospital stay; a reduction in door-to-needle time from 74 to 30 minutes; and a reduction in door-to-balloon from 110 to 90 minutes.
To evaluate the effect of the intervention, we compared KPIs from patients in group A hospitals at 12 months (after 2 cycles of the intervention, 1600 individuals) with those from patients from group B hospitals who had not yet received the intervention (1900 individuals; Figure 1 ). Generalized estimating equations model with an exchangeable correlation structure was used to account for correlation between individuals within the same hospital. Gaussian and log-binomial generalized estimating equations regressions were used for continuous and binary KPIs, respectively. All analyses were conducted at the level of the patient. The model was also adjusted for preintervention patient and hospital characteristics that differed (P<0.1) between the 2 groups. All analyses were done using SAS version 9.2.
Similar analyses were performed to investigate the effect of the intervention on prespecified clinical outcomes. All P values were based on a 2-sided Wald test, and the nominal level of α set to 5%. As is common practice in the analysis of data from large-scale trials in which all major outcomes are reported (many of which are correlated), no adjustment for multiple statistical testing was done. 19 Judgment about the effectiveness was, therefore, not based on the findings related to a single outcome but rather on totality of the evidence 
Survey of Health Professionals
Health professionals working in relevant departments in the 75 participating hospitals were invited to take part in the survey that assessed their perceptions, experiences, and the degree of engagement with the pathway intervention. Each hospital was requested to provide a list of health professionals directly using the pathways or involved in their implementation. These individuals included doctors working in emergency departments, cardiologists and other physicians working in inpatient and outpatient departments, nurses, and senior departmental and hospital administrators. The survey comprised of openand close-ended questions, as well as 6-point Likert Scale questions. Hard copies of the survey with reply-paid envelopes were mailed directly to each identified health professional, and deidentified forms were returned directly to the study coordinating center.
Qualitative Evaluation
A prespecified qualitative evaluation using an in-depth interviews with clinical staff was conducted in parallel with the main quantitative evaluation of effectiveness. The findings of this process evaluation are published as a companion article. 20 
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Results
Hospital and Patient Characteristics
Eighty-two potentially eligible hospitals were identified. Of these, 7 (8.5%) were excluded because of low patient volume or a subsequent decision not to participate. Pilot testing of the intervention occurred in 5 hospitals. The remaining 70 hospitals (45 level 3 and 25 level 2) were randomized (Figure 2 ).
For the entire study period from October 2007 and August 2010, data were collected from 15 141 patients (8049 patients from group A, 5731 from group B, and 1361 from pilot hospitals). Of these, 5976 (39.5%) had a final assigned diagnosis of STEMI, whereas non-ST-segment-elevation myocardial †Indicates variables significantly different between groups (P<0.1) and used as covariates in adjusted models.
Table 2. Patient Characteristics 12 Months After Intervention for Group A Hospitals and Preintervention for Group B Hospitals
Patients Group A n/N (%)* Group B n/N (%)* infarction and unstable angina pectoris were diagnosed in 2071 (13.7%) and 7094 (46.9%) patients, respectively. In the randomized comparison, data from 1600 patients at 12 months in group A hospitals were compared with preintervention data from 1900 patients in group B hospitals (Tables 1 and 2) .
Effects on KPIs
The use of clinical pathways was associated with a 11% absolute increase in the proportion of patients discharged on recommended therapies ( confounders, this remained statistically significant (P=0.004; Figure 3 ). There were no significant differences between the 2 groups for any of the remaining KPIs (all P>0.069; Figure  3 ). Similarly, there was no clear evidence of improvements in clinical outcomes (Figure 4) , although all point estimates of effectiveness favored the intervention. There was no evidence of heterogeneity in intervention effect by hospital type for any outcome (all P>0.05). KPIs for group A and B hospitals preintervention are provided in the Data Supplement Table. In supplementary trend analyses, there were significant improvements in hospital length of stay (P=0.001) and the proportion of patients discharged on appropriate medical therapy (P=0.0004) with successive cycles of the intervention ( Figure 5 ). However, for the remaining KPIs and for the clinical outcomes, there was no clear evidence of improvement over time.
Survey of Health Professionals
Responses were received from 71 of the 75 hospitals, with a response rate for participants of 90%. Characteristics of the 556 respondents who completed the health professional's survey are listed in Table 3 . Most (78.3%) were physicians aged between 21 to 40 years. Awareness of the intervention was high ( Figure 6A) ; 98.2% of respondents had heard of the intervention, and >80% had attended training sessions, used the pathway in clinical practice, and were aware of study reports. Health professionals' experience of the clinical pathways was positive ( Figure 6B ). More than 90% of respondents completely or strongly agreed that the pathways were valuable for the management of patients with ACS and that the program was important for improving quality of care.
Discussion
This large implementation study with randomized evaluation found that the proportion of patients discharged on appropriate medical therapy was increased with pathway implementation, but the routine use of a hospital-based clinical pathway did not otherwise enhance the quality of care provided to patients with ACS in China. In patients with an acute coronary event, there are 4 major aspects of care that have been shown to unequivocally save lives; rapid access to a hospital or a defibrillator, early reperfusion therapy for STEMI, early angiography and PCI in high-risk patients, and appropriate medical therapy for acute care and long-term secondary prevention. The CPACS-2 intervention was not designed to improve access to hospital, but for the remaining indicators where the intervention might be expected to have an effect, the clinical pathway did not seem to improve care except for discharge medical treatment. Observational studies, such as Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRU-SADE) study, 21 have reported a significant correlation between recommended medication use and in-hospital mortality at the hospital level, suggesting that for each 10% increase in the composite adherence to the American College of Cardiology/American Heart Association guidelines, there was a 10% decrease in the odds of in-hospital mortality by a trend analysis. 20 In our trial, a significant increase in the proportion of patients discharged on recommended therapies was achieved; however, differences in clinical outcomes were not statistically significant. A similar cluster randomized clinical trial (Brazilian Intervention to Increase Evidence Usage in Acute Coronary Syndromes [BRIDGE-ACS] trial) 22 also reported a significant improvement in the use of evidence-based therapies among patients with ACS in Brazil, following a multifaceted educational intervention; however, this study, like ours, had insufficient power to examine hard clinical outcomes. 22
Strengths and Limitations of the Study
Our study is the first rigorous evaluation of a hospital quality improvement initiative in China. This study uses a mixed methods approach, one which is increasingly recognized as valuable given the ability of one study to inform the findings of the other. 23 A limitation of this study relates to likely insufficient study power to reliably detect clinically meaningful differences in some KPIs, despite the large study size. Post hoc power calculations with the original intracluster coordination assumptions indicated power estimates of 80% to 90% for all KPIs except low-risk patients undergoing functional testing, which had the smallest cluster size. The main cause of overall inadequate power was higher actual versus assumed intracluster coordinations-when the actual intracluster coordinations were used, power was 60% to 70% except for the previously indicated KPI, as well as high-risk patients undergoing angiography where the intracluster coordination was large (0.46), reflecting substantial between-hospital variation.
The study is subject to other potential limitations, and the findings should be interpreted with these in mind. First, baseline measurements in group B hospitals could not take place at the same time as such measurements in group A because of funding and other resource constraints. Thus, for the randomized comparisons, we may not be able to fully account for any effects on ACS management attributable to secular changes rather than the intervention itself. Where differences did exist, we adjusted for measured variables with no change in our results or conclusions, but we cannot account for unmeasured or unknown factors. Second, the testing of multiple hypotheses increases the risk of type 1 error; however, we note the consistency in the direction of intervention effects on multiple outcomes. Rather than using somewhat arbitrary multiplicity adjustments, we chose to report the results of all the prespecified analyses 11 and interpret the results in light of the multiple tests conducted. Third, the unblinded nature of the study and the potential for nonconsecutive enrollment of patients could give rise to differential reporting of events. However, monitoring midway through the intervention did not demonstrate any evidence of under-reporting. Furthermore, a retrospective analysis comparing enrolled patients with eligible patients who were not enrolled showed that the 2 groups were similar in terms of mean age (P=0.28), sex (P=0.25), and in-hospital mortality (P=0.46).
The survey of health professionals involved in CPACS-2 suggested good awareness, use, and acceptance of the clinical pathways that were introduced. The findings from this survey, as well as from the accompanying qualitative evaluation, suggest that both the adoption of the intervention and the ability of the pathway to change practice were influenced by multiple external factors.
Conclusions
The introduction of clinical pathways for the management of ACS in a broad range of hospitals in China had a limited effect on measures of quality of care. These findings need to be understood in the context of the healthcare environment and health systems that have a direct bearing on the likelihood of effectiveness. Such factors are considered in the accompanying publication focused on the process evaluation and are relevant directly to major national health system reforms currently underway in China. Figure 6 . A, Awareness of the Clinical Pathways for Acute Coronary Syndromes-Phase 2 (CPACS-2) intervention among health professionals at participating hospitals; B, health professionals' experience of the CPACS-2 intervention at participating hospitals. ACS indicates acute coronary syndrome.
